- Home
- NIE vs ALLO Comparison
NIE vs ALLO Comparison
Compare NIE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NIE | ALLO |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | 152 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.3M | 722.1M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NIE | ALLO |
|---|---|---|
| Price | $26.15 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $8.35 |
| AVG Volume (30 Days) | 45.5K | ★ 5.9M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.78 | $1.04 |
| 52 Week High | $27.24 | $4.46 |
Technical Indicators
Market Signals| Indicator | NIE | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 54.73 |
| Support Level | $25.99 | $2.07 |
| Resistance Level | $26.92 | $2.25 |
| Average True Range (ATR) | 0.28 | 0.11 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 13.89 | 65.85 |
Price Performance
Historical ComparisonAbout NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).